Boston Scientific (NYSE: BSX) reported Q4 EPS of $0.45, $0.02 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $3.24 billion versus the consensus estimate of $3.24 billion.

GUIDANCE:

Boston Scientific sees Q1 2023 EPS of $0.42-$0.44, versus the consensus of $0.44.

Boston Scientific sees FY2023 EPS of $1.86-$1.93, versus the consensus of $1.93.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.